438 related articles for article (PubMed ID: 29145397)
1. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.
Zijlstra EE; Alves F; Rijal S; Arana B; Alvar J
PLoS Negl Trop Dis; 2017 Nov; 11(11):e0005877. PubMed ID: 29145397
[TBL] [Abstract][Full Text] [Related]
2. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
3. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
[TBL] [Abstract][Full Text] [Related]
4. Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
Burza S; Sinha PK; Mahajan R; Sanz MG; Lima MA; Mitra G; Verma N; Das P
PLoS Negl Trop Dis; 2014; 8(1):e2611. PubMed ID: 24392171
[TBL] [Abstract][Full Text] [Related]
5. Genome wide comparison of Leishmania donovani strains from Indian visceral leishmaniasis and para-kala-azar dermal leishmaniasis patients.
Sarraf NR; Mukhopadhyay S; Banerjee A; Das AK; Roy S; Chakrabarti S; Manna M; Saha P
Acta Trop; 2021 Nov; 223():106086. PubMed ID: 34389331
[TBL] [Abstract][Full Text] [Related]
6. Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination.
Kumar A; Singh VK; Tiwari R; Madhukar P; Rajneesh ; Kumar S; Gautam V; Engwerda C; Sundar S; Kumar R
Front Immunol; 2023; 14():1236952. PubMed ID: 37638047
[TBL] [Abstract][Full Text] [Related]
7. Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states.
Saurabh S; Roy P; Pandey DK; Ray D; Tarak S; Pandey R; Kumar D; Jamil S; Paulraj A; Kumar A; Dutta S
J Vector Borne Dis; 2020; 57(2):161-169. PubMed ID: 34290161
[TBL] [Abstract][Full Text] [Related]
8. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
9. The immunology of post-kala-azar dermal leishmaniasis (PKDL).
Zijlstra EE
Parasit Vectors; 2016 Aug; 9(1):464. PubMed ID: 27553063
[TBL] [Abstract][Full Text] [Related]
10. Clinico-epidemiological analysis of Post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: a hospital based retrospective study.
Ramesh V; Kaushal H; Mishra AK; Singh R; Salotra P
BMC Public Health; 2015 Oct; 15():1092. PubMed ID: 26503551
[TBL] [Abstract][Full Text] [Related]
11. Inferring transmission trees to guide targeting of interventions against visceral leishmaniasis and post-kala-azar dermal leishmaniasis.
Chapman LAC; Spencer SEF; Pollington TM; Jewell CP; Mondal D; Alvar J; Hollingsworth TD; Cameron MM; Bern C; Medley GF
Proc Natl Acad Sci U S A; 2020 Oct; 117(41):25742-25750. PubMed ID: 32973088
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of a combined camp approach for vector control together with active case detection of visceral leishmaniasis, post kala-azar dermal leishmaniasis, tuberculosis, leprosy and malaria in Bangladesh, India and Nepal: an exploratory study.
Banjara MR; Kroeger A; Huda MM; Kumar V; Gurung CK; Das ML; Rijal S; Das P; Mondal D
Trans R Soc Trop Med Hyg; 2015 Jun; 109(6):408-15. PubMed ID: 25918216
[TBL] [Abstract][Full Text] [Related]
13. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
[TBL] [Abstract][Full Text] [Related]
14. The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and meta-analysis.
Pijpers J; den Boer ML; Essink DR; Ritmeijer K
PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007173. PubMed ID: 30742620
[TBL] [Abstract][Full Text] [Related]
15. Quantifying the Infectiousness of Post-Kala-Azar Dermal Leishmaniasis Toward Sand Flies.
Mondal D; Bern C; Ghosh D; Rashid M; Molina R; Chowdhury R; Nath R; Ghosh P; Chapman LAC; Alim A; Bilbe G; Alvar J
Clin Infect Dis; 2019 Jul; 69(2):251-258. PubMed ID: 30357373
[TBL] [Abstract][Full Text] [Related]
16. Visceral Leishmaniasis-HIV Coinfection as a Predictor of Increased
Cloots K; Marino P; Burza S; Gill N; Boelaert M; Hasker E
Front Cell Infect Microbiol; 2021; 11():604117. PubMed ID: 33777831
[TBL] [Abstract][Full Text] [Related]
17. Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India.
Goyal V; Das VNR; Singh SN; Singh RS; Pandey K; Verma N; Hightower A; Rijal S; Das P; Alvar J; Bern C; Alves F
PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008429. PubMed ID: 32687498
[TBL] [Abstract][Full Text] [Related]
18. Post-kala-azar dermal leishmaniasis: does it play a role in the transmission of Leishmania donovani in the Sudan?
El Hassan AM; Khalil EA
Trop Med Int Health; 2001 Sep; 6(9):743-4. PubMed ID: 11555443
[TBL] [Abstract][Full Text] [Related]
19. Detection of asymptomatic Leishmania infection in Bangladesh by antibody and antigen diagnostic tools shows an association with post-kala-azar dermal leishmaniasis (PKDL) patients.
Owen SI; Hossain F; Ghosh P; Chowdhury R; Hossain MS; Jewell C; Cruz I; Picado A; Mondal D; Adams ER
Parasit Vectors; 2021 Feb; 14(1):111. PubMed ID: 33597000
[TBL] [Abstract][Full Text] [Related]
20. Post-kala-azar dermal leishmaniasis.
Zijlstra EE; Musa AM; Khalil EA; el-Hassan IM; el-Hassan AM
Lancet Infect Dis; 2003 Feb; 3(2):87-98. PubMed ID: 12560194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
